1. Home
  2. IBRX vs PAR Comparison

IBRX vs PAR Comparison

Compare IBRX & PAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IBRX
  • PAR
  • Stock Information
  • Founded
  • IBRX 2014
  • PAR 1968
  • Country
  • IBRX United States
  • PAR United States
  • Employees
  • IBRX N/A
  • PAR N/A
  • Industry
  • IBRX Biotechnology: Biological Products (No Diagnostic Substances)
  • PAR Office Equipment/Supplies/Services
  • Sector
  • IBRX Health Care
  • PAR Miscellaneous
  • Exchange
  • IBRX Nasdaq
  • PAR Nasdaq
  • Market Cap
  • IBRX 2.3B
  • PAR 2.4B
  • IPO Year
  • IBRX N/A
  • PAR N/A
  • Fundamental
  • Price
  • IBRX $2.53
  • PAR $37.88
  • Analyst Decision
  • IBRX Strong Buy
  • PAR Strong Buy
  • Analyst Count
  • IBRX 6
  • PAR 7
  • Target Price
  • IBRX $9.83
  • PAR $78.43
  • AVG Volume (30 Days)
  • IBRX 10.3M
  • PAR 961.3K
  • Earning Date
  • IBRX 11-11-2025
  • PAR 11-07-2025
  • Dividend Yield
  • IBRX N/A
  • PAR N/A
  • EPS Growth
  • IBRX N/A
  • PAR N/A
  • EPS
  • IBRX N/A
  • PAR N/A
  • Revenue
  • IBRX $56,600,000.00
  • PAR $418,022,000.00
  • Revenue This Year
  • IBRX $629.94
  • PAR $29.03
  • Revenue Next Year
  • IBRX $109.91
  • PAR $15.00
  • P/E Ratio
  • IBRX N/A
  • PAR N/A
  • Revenue Growth
  • IBRX 4227.22
  • PAR 45.74
  • 52 Week Low
  • IBRX $1.83
  • PAR $37.29
  • 52 Week High
  • IBRX $7.48
  • PAR $82.24
  • Technical
  • Relative Strength Index (RSI)
  • IBRX 47.77
  • PAR 22.74
  • Support Level
  • IBRX $2.42
  • PAR $37.42
  • Resistance Level
  • IBRX $2.75
  • PAR $39.25
  • Average True Range (ATR)
  • IBRX 0.13
  • PAR 1.34
  • MACD
  • IBRX -0.01
  • PAR 0.13
  • Stochastic Oscillator
  • IBRX 22.88
  • PAR 8.14

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

About PAR PAR Technology Corporation

PAR Technology Corp is a foodservice technology company providing omnichannel cloud-based software and hardware solutions to the restaurant industry in three restaurant categories - quick service, fast casual, and table service - and the retail industry, including convenience and fuel retailers (C-Stores). The company's product and service offerings include point-of-sale, customer engagement and loyalty, digital ordering and delivery, operational intelligence, payment processing, hardware, and related technologies, solutions, and services. The company generates revenue from subscription service, Sale of Hardware products, and Professional Service.

Share on Social Networks: